News Biogen protects Tecfidera via $1.25bn deal with Forward Biogen could also pay royalties to Forward.
News Japan follows UK in GSK's comeback tour for Blenrep The revitalisation of GSK's blood cancer therapy Blenrep continues with a second approval, in Japan, as a second-line treatment for multiple myeloma.
Market Access Sponsored Bridging research and clinical guidelines – interactive stra... Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.
